AAminove
Back to library

PT-141 (Bremelanotide)

Human RCTApproved medicine

Also known as: Vyleesi, Bremelanotide

CosmeticHypoactive sexual desire disorder (approved, women)

Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.

Overview

A melanocortin-receptor agonist approved as bremelanotide (Vyleesi) for premenopausal women with HSDD. Other uses are off-label.

Mechanism

Activates melanocortin receptors in the central nervous system influencing sexual response.

Evidence

Human RCTWhat does this mean?

Strong within its approved indication; off-label use is not supported by that approval.

Community-reported information

Prescription medicine dosed per label and clinician within its indication.

General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.

Half-life

~2.7 hours.

Storage

Room temperature per label.

Commonly reported side effects

  • Nausea
  • Flushing
  • Headache
  • Injection-site reactions

Legal status by region

  • USFDA-approved (Vyleesi) for a specific indication; prescription only.

Legal status changes over time; verify locally before relying on this.

Citations